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genetically engineered viruses, which are able to selectively infect and kill the cancer cells 
causing no harm to normal cells. Adenoviruses are the most commonly used viruses in the gene 
therapy field and their oncolytic variants are currently under evaluation in many clinical trials. 
The cell killing properties of oncolytic adenoviruses against the cancer cells have been known 
for a long time. In addition, it is known that they can activate immune system. To achieve more 
selective and effective antitumor effects several modifications of oncolytic adenoviruses have 
been studied. During my internship I worked on the development of a new cancer vaccine 
platform based on peptide-coated conditionally replicating adenovirus (PeptiCRAd). The 
PeptiCRAd technology consists of a serotype 5 adenoviruses which are coated with tumor- 
derived peptides. 
 
The aim of the thesis was to evaluate the antitumor efficacy of the PeptiCRAd. The cytopathic 
effects of the PeptiCRAd were studied in vitro using human adenocarcinoma cell line, A549. In 
this experiment three different treatments were used to study the cytopathic effects of the 
PeptiCRAd and Ad5Δ24-CpG- virus or polyK-SIINFEKL- peptide alone. The cell viability was 
assayed using MTS reagent and quantified by spectrophotometer. The antitumor effects were 
also studied in vivo using immunocompetent C57BL/6 mice bearing B16-OVA melanoma 
tumors. Tumor-bearing mice were treated with Ad5Δ24-CpG- virus, SIINFEKL- peptide or the 
PeptiCRAd. To evaluate the antitumor effects, tumor volume was observed after the treatments. 
 
In this study, I show that PeptiCRAd and Ad5Δ24-CpG- virus both have oncolytic effects in 
vitro against A549 cells. In vitro Ad5Δ24-CpG- virus showed significantly better cytopathic 
effects at high concentration compared to PeptiCRAd. In vivo the PeptiCRAd showed strongest 
antitumor effect on the growth of established tumors. At the end of the experiment the volume 
of the tumor was significantly smallest in the PeptiCRAd group.     
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Tiivistelmä/Referat – Abstract 
Onkolyyttisiä viruksia on tutkittu laajasti syövän hoidossa. Ne ovat geneettisesti muokattuja 
viruksia, jotka pystyvät selektiivisesti infektoimaan ja tappamaan syöpäsoluja vahingoittamatta 
normaaleja soluja. Adenovirukset ovat yleisimmin käytettyjä viruksia geeniterapiassa ja näiden 
virusten muunnoksia arvioidaan useissa kliinisissä kokeissa tällä hetkellä. Onkolyyttisten 
adenovirusten syöpäsoluja tappavat ominaisuudet on tiedetty jo pitkään. Tämän lisäksi 
tiedetään, että ne voivat aktivoida immuunijärjestelmää. Jotta saavutettaisiin selektiivisempiä ja 
tehokkaampia kasvainta tuhoavia vaikutuksia, useita muunnelmia onkolyyttisistä 
adenoviruksista on tutkittu. Harjoitteluni aikana olin mukana kehittämässä uutta 
syöpärokotemallia, joka perustuu peptidillä päällystettyyn, ehdollisesti replikoituvaan 
adenovirukseen (PeptiCRAd). PeptiCRAd:n teknologia koostuu serotyypin 5 adenoviruksista, 
jotka päällystetään kasvaimesta peräisin olevilla peptideillä.  
 
Työn tavoitteena oli arvioida PeptiCRAd:n tehoa kasvainta vastaan. PeptiCRAd:n soluja 
tappavaa tehoa tutkittiin in vitro käyttämällä ihmisen adenokarsinooman solulinjaa, A549. 
Soluja tappavia vaikutuksia tutkittiin käsittelemällä soluja sekä PeptiCRAd:lla että pelkästään 
Ad5Δ24-CpG- viruksella ja polyK-SIINFEKL- peptidillä. Solujen viabiliteetti tutkittiin 
käyttämällä MTS reagenssia ja solujen määrä määritettiin spektrofotometrisesti. Kasvainta 
tuhoavia vaikutuksia tutkittiin myös in vivo normaalin immuunijärjestelmän omaavilla 
C57BL/6- hiirillä, jotka kantoivat B16-OVA melanooman kasvaimia. Hiirten kasvaimia 
hoidettiin Ad5Δ24-CpG- viruksella, SIINFEKL- peptidillä tai PeptiCRAd:lla. Kasvainta 
tuhoavien vaikutusten tutkimista varten, kasvaimen kokoa seurattiin hoitojen jälkeen.  
 
Tässä työssä osoitin, että PeptiCRAd:lla ja Ad5Δ24-CpG- viruksella molemmilla on 
kasvainsoluja tappavia vaikutuksia in vitro A549- syöpäsoluja kohtaan. Ad5Δ24-CpG- virus 
osoitti in vitro merkittävästi parempia soluja tappavia vaikutuksia suuremmilla pitoisuuksilla 
kuin PeptiCRAd. In vivo PeptiCRAd osoitti selkeimmin kasvainta tuhoavia vaikutuksia 
vaikuttamalla muodostuneiden kasvainten kasvuun. Kokeen lopussa kasvainten koko oli 
merkittävästi pienin PeptiCRAd ryhmässä. 
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1. INTRODUCTION 
 
Cancer cells derive from normal cells that have lost the control upon the proliferation 
cycle, thus they divide with no regulation. Local cancer treatments consist of surgery 
and radiotherapy; these strategies are often complemented by systemic therapies that 
involve the use of chemotherapeutic drugs. Nevertheless, the toxic effects represent the 
main limitation for the use of these drugs, because they do not kill only cancer cells but 
also normal cells. For this reason, more and more resources have been invested in the 
development of selective approaches and, among these, oncolytic adenoviruses have 
been the subject of a great number of preclinical and clinical trials. 
Immunotherapy is a growing branch of science in the field of cancer therapy. 
Interleukins (ILs) and monoclonal antibodies against immune checkpoint inhibitors 
(ICIs) are used to regulate immune system. ILs stimulate the immune system while ICIs 
block the inhibition mediated by CTLA-4 or PD-1 engagement on T-cells. The problem 
is that these approaches are too broad and not specific. 
Some tumors overexpress specific proteins and this feature can be utilized when 
developing a new peptide vaccination. MAGE (melanoma antigen gene) and gp100 
(glycoprotein 100) have been studied as a target for cancer therapies. Targeting these 
melanoma-associated antigens represents a more specific approach than previous ones. 
However, current cancer vaccine therapies are struggling in finding appropriate and 
potent adjuvants. In this context, adenoviruses can represent a new class of adjuvants 
for peptide vaccines. 
The adenoviruses are the most commonly used viruses in the gene therapy field (Ginn et 
al. 2013). In particular, the oncolytic viruses are adenoviruses engineered to selectively 
infect and kill the cancer cells causing no damage to the normal tissues (Guo et al. 
2008). In addition to have an antitumor activity due to the ability to lyse tumor cells, the 
oncolytic viruses are also able to stimulate the immune system (Kirn 2001). The 
immune response is, however, mainly directed against the virus rather than the tumor. 
In the present work, we want to address this specific issue. The main aim is to increase 
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the antitumor response exploiting the oncolytic viruses´ immunogenic potential. For this 
reason, our laboratory has developed a new cancer vaccine platform, PeptiCRAd.  
 
 
2. MELANOMA 
 
In 2013 skin melanoma was the sixth common cancer type in Finland among male and 
female (Finnish Cancer registry, 2015). The incidence of skin melanoma has increased 
during the last decades faster than other more common cancer types. It can be observed 
in figure 1 that over the period from 1980 to 2013 the new cases of skin melanoma have 
more than doubled among female and male. In Nordic countries the incidence increased 
2.6- fold in male and 2.4- fold in female over this 33 years period. Although the primary 
cutaneous melanoma can be operated by surgery, there is a need for more effective and 
selective treatments for advanced melanoma. Melanoma expresses several tumor- 
associated antigens, which are potential targets to new cancer therapies.   
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Figure 1. The incidence rates of the skin melanoma in Nordic countries among female 
and male. Data are presented at age-specific rate (ASR) per 100.000 person-years from 
1980 to 2013. In 1980 the incidences were 15.05 (male) and 16.97 (female), in 2010 the 
numbers were 38.39 (male) and 41.40 (female). (Engholm et al. 2015) 
 
 
3.  CANCER IMMUNOTHERAPY 
 
Immunotherapy has become important field of science in the last decade. Aim of the 
immunotherapy is to activate the immune system as a defense mechanism against a 
disease. The immunotherapy can be divided into passive and active form. In passive 
immunotherapy patient receives “ready” components e.g. antibodies or cells, which help 
 4 
 
to fight against the disease. In active immunotherapy the idea is to create an immune 
response against the target cells inside the host.  
The immune system can recognize a wide variety of pathogenic structures and fight 
against all kind of diseases, also the cancer. After recognizing the unfamiliar substance 
defense mechanisms are engaged, leading to the activation of the immune response. 
Among leukocytes, T- and B-cells are the effectors of the adaptive and humoral 
response respectively. These cells can recognize a wide variety of antigens but are 
activated only when a specific antigen can bind to their receptor. B- cells can bind 
antigen directly with the surface receptor, B- cell receptor (BCR), while T-cell can’t 
recognize the antigens directly. In fact, T-cells recognize antigens only when presented 
on major histocompatibility complex (MHC) - molecules by professional antigen 
presenting cell (APC). T-cells are activated when MHC- antigen complex bind to T-cell 
receptor (TCR). Activated T-cells start to produce differentiated effector T-cells e.g. 
cytotoxic T-cells (CTL) that can, for instance, kill tumor cells that express particular 
antigens. (Janeway’s Immunobiology 2012) 
 In immunotherapy T-cells have a pivotal role and these lymphocytes are often the 
target of different therapies: monoclonal antibodies, cytokines, immune checkpoint 
inhibitors and vaccines. In this review the focus is on cancer immunotherapy, more 
precisely the medical treatments of melanoma and oncolytic adenoviruses. 
In cancer immunotherapy the challenge is how to activate the immune system against 
the cancer cells. This task is made difficult by the fact that malignant cells are not 
foreign pathogens. In fact, some of the tumor proteins are also expressed in normal 
tissues, so there is tolerance against these targets. Nevertheless, tumor cells overexpress 
some proteins, which are potential targets. 
 
3.1. Immunotherapy of melanoma 
 
The location and the stage of melanoma influence what type of treatment is chosen. 
Local and early stage of melanoma can still be cured by means of surgery but advanced 
melanoma is still in need of effective and specific treatments. The drug treatments for 
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metastatic melanoma have been evolved significantly in the past few years and several 
drugs have been approved by U.S Food and Drug Administration (FDA) and European 
Medicines Agency (EMA).  
Cytokines are small proteins, normally produced by our body, which control the cell 
behavior. This class of molecules include, for instance several types of interleukins and 
interferons. The effects of interleukins are associated with the induction of T-cell 
activation and proliferation. They regulate immune responses and are produced by T-
cells. Some of these molecules are also used to treat melanoma, including IL-2 and IL-
6. (Janeway’s Immunobiology 2012)  
Interleukin- 6 (IL-6) has several effects on the immune system. It has been evaluated as 
a biomarker in patients with metastatic melanoma. In several studies, it has been 
observed that IL-6 baseline levels in serum are significantly higher in patients with 
metastatic melanoma (Mouawad et al. 1996; Tas et al. 2005). Mouawad (1996) et al 
took also into account the tumor burden. They observed that IL-6 levels were 
significantly higher in patients with high tumor burden when compared to patients with 
low tumor burden (Mouawad et al. 1996).  
FDA approved the first IL-2 drug for the treatment of metastatic melanoma in 1998. 
High dose IL-2 therapy has been found to be effective in advanced melanoma patients, 
although higher doses increase the risk of severe side effects. Due to the toxic effects of 
IL-2, especially with high doses, it has been studied also with lower doses and 
combined with other treatments e.g. peptide vaccination. In fact, Smith (2008) and 
coworkers studied the overall response in patients with metastatic melanoma treated 
with IL-2 alone and combined with different peptides. According to the study, IL-2 
showed moderate response in patients with metastatic melanoma (Smith et al. 2008). 
Interestingly, in the patients who received IL-2 with different combination of peptides 
the response was increased moderately (Smith et al. 2008; Schwartzentruber et al. 
2011).  
Schwartzentruber (2011) et al carried out a phase 3 clinical trial with 185 patients 
bearing stage IV or locally advanced stage III cutaneous melanoma. The primary aim 
was to evaluate clinical responses of different IL-2 treatments, and as a secondary target 
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their toxic effects and progression- free survival. The groups received either IL-2 alone 
or vaccine- IL-2 combination, where the vaccine contained both gp100- peptide and 
Freund’s adjuvant. Vaccine-IL-2 combination showed significantly better efficacy 
compared to IL-2 therapy, as overall responses were 16 % and 6 % (P=0.03) 
respectively (Schwartzentruber et al. 2011).   
Adoptive cell therapy has been in clinical use for three decades and numerous studies 
have been conducted on its efficacy against melanoma (Ellebaek et al. 2012; Khammari 
et al. 2014). The adoptive cell therapy is based on the isolation of specific cells from the 
blood after the immune system has been boosted with other treatments. Isolated cells, 
e.g. tumor specific T-cells, are expanded in vitro and then re-infused into the patient. 
Promising results have been presented with combination of tumor infiltrating 
lymphocytes (TILs) and IL-2 in advanced melanoma patient. Ellebaek (2012) et al 
studied the combination treatment in metastatic melanoma patients. All the patients 
were treated with lymph depleting chemotherapy, TILs and low dose IL-2. In this trial 
scientists showed that it’s possible to achieve long-lasting responses even with low dose 
IL-2 treatment if used in combination with TILs (Ellebaek et al. 2012).  
The immune system’s efficacy against cancer can be also increased by disrupting the 
suppressive mechanisms that block the activity of T-cells. In particular, cytotoxic T-
lymphocyte antigen 4 (CTLA-4) and Programmed Death-1 (PD-1) receptors on the 
surface of lymphocytes inhibit the activation of T-cells. Through these receptors, 
antigen-specific T-cell responses are controlled by inhibitory signals that are mediated 
by PD-L1, PD-L2, CD80 and CD86. (Janeway’s Immunobiology 2012; Ritprajak and 
Azuma 2015)  
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Figure 2.  Immune checkpoint inhibitors Nivolumab (anti-PD-1) and Ipilimumab (anti-
CTLA-4) can block the co-inhibitory pathways by interacting PD-1 and CTLA-4 
receptors. Figure modified (Ritprajak and Azuma 2015). TCR (T-cell receptor), Ag 
(Antigen), APC (Antigen presenting cell) 
 
These ligand-receptor interactions can be blocked with antibodies. FDA and European 
Medicines Agency (EMA) approved in 2011 the first CTLA-4 blocking antibody, 
Ipilimumab, indicated for the treatment of unresectable or metastatic melanoma in 
adults (Hanaizi et al. 2012). Ipilimumab binds to CTLA-4 and prevents interaction with 
its ligands: CD80/CD86 (figure 2). This inhibition has been shown to increase T-cell 
activation and proliferation. Another approach to increase T-cell activation is to block 
another receptor on the surface of T-cell that mediates inhibitory effect via PD-1 
pathway. FDA and EMA approved in 2014 Nivolumab, which is an anti-PD-1 antibody.   
Ipilimumab has been studied also in combination with cancer vaccine strategies. Hodi 
(2010) and coworkers studied ipilimumab and gp100 both alone and in combination for 
the treatment of advanced melanoma. They observed that overall survival in ipilimumab 
alone and ipilimumab in combination with gp100 groups were better than in gp100 
group. The median overall survival times were 10.0 months (Ipilimumab-gp100), 10.1 
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months (Ipilimumab) and 6.4 months (gp100). In this study also adverse events were 
evaluated. Frequent immune-related events were observed, with 60 % of patients in 
ipilimumab groups and 32 % of patients in gp100 group experiencing toxicity. To date 
FDA and EMA have been approved in total three immune checkpoint antibodies for the 
treatment of metastatic melanoma. The immune checkpoint inhibitors have been proved 
to be more effective and selective compared to IL- therapies but the safety profile could 
still be improved. Therapeutic cancer vaccines might provide an effective and selective 
treatment of cancer with minor side effects. (Hodi et al. 2010) 
 
3.2. Cancer vaccines and tumor antigens 
 
Vaccines are designed to boost our own immune system and to protect us against 
different pathogens by creating an immunological memory. This memory will then 
protect us when we will encounter the specific pathogen.  
Vaccines usually contain pathogens that are weakened or killed so that they are not able 
to cause the disease. However, the immune system can still recognize the proteins from 
the microorganism. As a consequence, adaptive immune and humoral responses are 
engaged resulting the stimulation of B– and T-cells. Part of these lymphocytes will 
eventually differentiate into memory cells, which are responsible for the long-term 
immunity. The creation of this long-lasting immunity is the aim of the vaccination. To 
obtain adaptive response against the pathogen, vaccines need an adjuvant to boost and 
assist the immunization. (Janeway’s Immunobiology 2012) 
Cancer vaccines can be divided in i) preventive and ii) therapeutic vaccines. In 
preventive vaccination a pathogen is administered to a healthy person, who hasn’t 
encountered the pathogen yet. By introducing the priming dose into the body, the 
immune system responds by producing antibodies against the pathogen. The aim of the 
preventive cancer vaccines is to elicit immune responses against pathogen related to 
cause or contribute the development of cancer (Frazer et al. 2007). Preventive cancer 
vaccines prevent viral infections, for example human papilloma virus (HPV), which can 
result in cancer development (Frazer et al. 2007). Therapeutic cancer vaccines are 
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designed to activate or boost immune responses in cancer patients against cancer, for 
example targeting to cancer derived proteins (i.e. tumor antigens). Several tumor 
associated antigens (TAA) have been studied for the treatment of melanoma during the 
last decades e.g MZ2-E and gp100 (Brichard et al. 1993; Hodi et al. 2010).  
Pmel17 (gp100) is integral membrane glycoprotein which is located in melanocytes 
(Kawakami et al. 1994). This tumor antigen is expressed by both normal melanocytes 
and melanoma cells (Overwijk et al. 1998). As was discussed in previous chapter 3.1 it 
was observed in clinical trials that it was more effective in combination with 
ipilimumab.  
The expression of melanoma antigen (MAGE) coding gene family was reported in 
various tumor types. Van der Bruggen (1991) and coworkers evaluated the expression 
of MAGE-1 and related genes MAGE-2 and MAGE-3 in various tumor and normal 
cells. They observed that some melanomas expressed MAGE-1, -2 and -3 genes 
whereas some of them expressed only MAGE-2 and MAGE-3. All of these three genes 
were also expressed in other tumor types. The expression of MAGE genes is usually 
low or undetectable in different normal cells e.g. muscle, skin, lung and liver (Van der 
bruggen et al. 1991). MAGE-1 gene codes MZ2-E antigen, which is presented by class I 
MHC molecule HLA-A1. Interestingly these antigens are expressed in the cancer cells, 
which make them possible targets for immunotherapy. (Van der bruggen et al. 1991; 
Brichard et al. 1993) 
Kruit (2013) et al carried out a phase 2 clinical trial with 72 patients bearing MAGE-
A3- expressing melanoma tumor. The efficacy of MAGE protein in combination with 
two different adjuvants was studied. One of these adjuvants featured CpG islands in its 
structure to boost the immunity by engaging Toll-like Receptor 9 (Janeway’s 
Immunobiology 2012). They observed that the coadministration of MAGE-A3 protein 
with immunostimulant bearing the addition of CpG islands induced better cellular and 
humoral response. (Kruit et al. 2013) 
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4. ONCOLYTIC VIRUSES 
 
4.1. Viral infection 
 
Viruses are parasites that are not able to multiply or express their genes independently 
but need a host to produce their important structural proteins. Before the replication of 
virus DNA can occur, virus has to enter the cell. Virus attaches to the host cell surface 
by binding specific receptor and penetrates into the cell usually via receptor mediated 
endocytosis. After penetration the viral capsid breaks partly or completely and genome 
is released. Following the release of virus genome it can take advantage of host’s 
cellular mechanism to produce its functional and structural proteins. Viral proteins are 
assembled and new viral particles are released out of the host cell. Cell lysis is 
necessary for some non-enveloped viruses to release new viral particles out of the host 
cell. The structure of the virus and target cell has an influence on how virus enters the 
cell and how genome is released. However, host cell has its own defense mechanism 
against virus infection. Normally if the cells are infected with virus or their DNA is 
damaged, they try to activate different repair mechanisms. If they don’t manage to 
repair the damage they will initiate apoptosis. (Solunetti 2015) 
 
4.2.  Adenoviruses  
 
Adenoviruses consist of non-enveloped icosahedral protein capsid which covers its 
linear DNA genome and core proteins. Adenoviruses are the most commonly used 
viruses in the gene therapy field and over 40 different serotypes have been discovered. 
Adenovirus 2 (Ad2) and Ad5 are widely used serotypes in gene therapy. (Norman et al. 
2001; Ginn et al. 2013) 
Adenoviruses have several advantages that make them suitable platform for vaccines. 
One of the benefits is that the structure and functions of these viruses are well 
characterized. Adenovirus can enter the cells by binding with surface proteins to host 
cell receptor. On the surface of capsid there are three important proteins hexon, penton 
and fiber which has crucial role in adenovirus entry into the cell. Several receptors have 
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been proposed to be involved in the attachment of adenoviruses e.g Coxsackievirus and 
adenovirus receptor (CAR), MHC class I, sialic acid and αvβ integrins (Bergelson et al. 
1997; Arnberg et al. 2000; Davison et al. 2001). 
It is reported in studies that CAR mediated internalization to the cells is main pathway 
for Ad5 but also the integrins are important (Bergelson et al. 1997). Initial attachment of 
the virus occurs through the fiber knob domain which binds to host cell receptor, CAR. 
After this, Arg-Gly-Asp (RGD) sequence which is present in virus penton base binds to 
the cell surface integrins promoting virus internalization. Davison et al studied 
interactions between Ad5 and its receptors in vitro using several lung adenocarcinoma 
cells (A549, H322 and H441). They observed that cell surface αvβ1-integrin is involved 
with Ad5 infection. It was also shown that uptake by these cells is MHC class I 
independent and CAR dependent. (Davison et al. 2001)  
Over the years adenoviruses have been engineered and modified to improve selectivity 
and efficacy. The genes in the genome of adenovirus can be divided into two groups, 
early (E) and late (L) genes. Early genes are important for virus DNA replication, while 
late genes encode all the structural proteins that virus requires.  
As mentioned earlier in this chapter, host cell has the ability to defend itself against 
viral infection. Retinoblastoma (Rb) and p53 are tumor suppressor proteins, which 
promote apoptosis in case of DNA damage or cell infection (Lowe et al. 1993; Lee et al. 
1996). Therefore to achieve effective replication in host cells, tumor suppressor 
pathways have to be blocked. Figure 3 illustrates several pathways used by adenovirus 
to inhibit the normal apoptosis of infected cells. Adenovirus’ early genes express 
proteins that bind to p53, hence inhibiting its activity: E1A, E4-ORF3 and E1B-55k. By 
binding to Rb, E1A protein inhibits the apoptosis and infected cells synthesize new viral 
particles. E1B-55k and E4-ORF3 proteins allow the cell growth and replication by 
inhibiting p53 pathway. The knowledge of this mechanism allowed for the modification 
of adenoviruses’ genome, making them replication selective. In fact, oncolytic 
adenoviruses represent a particular class of conditionally replicating adenoviruses 
(CRAds).  
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Figure 3. Adenovirus can inhibit p53 pathway across several adenoviral proteins. a) 
Adenoviral protein, E1A can bind to retinoblastoma Rb, which initiates the signaling 
cascade leading to inhibition of MDM2. This results an increase in p53 levels. b) E1B-
55k protein can bind to p53 inhibiting transcription of p53 gene and promoting its 
degradation. c) E4-ORF3 protein deactivate p53 by mediating the methylation of 
promoters of p53 genes. (Ryan 2010) 
 
4.3. Oncolytic adenoviruses 
 
Oncolytic viruses have been studied as a cure of cancer and their cytopathic effects to 
the cancer cells have been known for decades (Taylor et al. 1971). They can infect both 
the normal and the cancer cells because CAR receptors are expressed also by normal 
cells. Their genome is, however, modified in order to allow the full replication process 
only in the cancer cells. Therefore, they are able to lyse only the tumor cells. In fact, 
they are used as the cancer treatments due to their ability to specifically infect and lyse 
the cancer cells, while the normal cells remain unharmed. To improve the selectivity 
and therapeutic efficacy of gene therapy vectors, genetic engineering has been used to 
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produce replication selective and replication defective adenoviruses. As discussed 
earlier in chapter 4.2, the E genes are particularly important for the viral replication.  
It is known that in many cancer types genes encoding tumor suppressor proteins, p53 
and Rb, are frequently mutated or deleted. Hence, defense mechanisms in response to 
viral infection (e.g apoptosis) are impaired. This difference between malignant cells and 
normal cells is exploited by oncolytic adenoviruses. 
CRAds bear deletions in early genes that encode the dysfunctional proteins, such as 
E1A or E1B-55k, hence they are not able to bind Rb or p53 proteins and proceed 
through their replication cycle. This means that adenoviruses carrying these 
modifications can’t replicate in normal cells and this mutation prevents them to lyse 
normally functioning cells. On the contrary, cancer cells have p53 and Rb proteins 
frequently mutated, hence CRAds can replicate, produce new viral particles and finally 
lyse the cells. (Bischoff et al. 1996; Lee et al. 1996; Heise et al. 1997) 
 
4.4. Oncolytic vaccines 
 
The ability of the viruses and the adenoviruses to activate the immune system makes 
them suitable platforms for immunotherapy. In particular, the oncolytic adenoviruses 
represent a promising vaccine platform thanks to their dual mode of action: i) direct 
lysis of the cancer cells; ii) activation of the immune system. These properties can be 
improved and, for instance, the immunogenicity can be increased by arming the virus 
with immunostimulatory genes that will lead to the production of cytokines by the 
infected cell (e.g. IL-2 and TNFα).  
The first oncolytic virus, ONYX-015/H101, was approved in China 2005 for the 
treatment of cancer. ONYX-015 is an adenovirus which has deletion in E1B gene area 
and it’s unable to encode E1B-55kDa protein (Heise et al. 1997). As described in 
previous chapter, due to this deletion it can replicate selectively in the cancer cells 
because they lack functional p53. Another example of an oncolytic virus which exploits 
the tumor mutations is the Ad5Δ24. Ad5Δ24 is an adenovirus that has a 24-base-pair 
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(Δ24) deletion in E1A gene region (Heise et al. 2000). Due to this deletion, the virus is 
replication selective in the cancer cells. 
Toll-like receptors (TLRs) can recognize and bind pathogen-associated molecular 
pattern (PAMP) structures and activate innate immune system. When TLRs are 
activated they induce immune system to activate antigen presenting cells like dendritic 
cells (DC). This could lead to a more effective presentation of antigens and enhanced 
specific T-cell responses for the coadministered antigen. (Janeway’s Immunobiology 
2012)  
Previous studies indicate that TLR-9 mediates cellular responses by binding 
unmethylated CpG in bacterial DNA (Hemmi et al. 2000). Cerullo (2012) et al 
developed the first genetically modified adenovirus backbone which was able to boost 
the TLR-9 stimulation resulting in an increased antitumor efficacy (Cerullo et al. 2012). 
This virus has as a basic structure the modified form of adenovirus serotype 5 (Ad5); 
Ad5Δ24-CpG. Besides the virus has deletion (Δ24) in E1A gene region the structure 
contains inserted DNA sequence called CpG islands.   
The antitumor effect of the Ad5Δ24-CpG virus was studied in vitro and in vivo. In vitro 
experiments were carried out with several human tumor cell lines: A549, SKOV3, 
PC3MM3 and Hela cells (figure 4). Ad5Δ24-CpG virus showed cytolytic effects but it 
wasn’t more effective than the normal Ad5Δ24 in vitro. (Cerullo et al. 2012) 
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Figure 4. The oncolytic efficacy of Ad5Δ24-CpG in different human cancer cell lines: 
A549, SKOV3, PC3MM3 and Hela cells. (Cerullo et al. 2012) 
 
An in vivo experiment was carried out using the immunocompetent C57BL/6 mice 
bearing B16-OVA melanoma tumors and also the xenograft model in nude mice 
carrying A549 lung cancer tumors (figure 5 and 6). Ad5Δ24-CpG significantly reduced 
the tumor growth in both tumor models. According to this study Ad5Δ24-CpG showed 
improved efficacy compared to normal oncolytic adenovirus in both models. It was also 
observed that improved effects were achieved when CpG islands were inserted to the 
genome compared to separate administration of Ad5Δ24 and CpG oligonucleotides. 
Tumors and spleens were analyzed to assess antitumor immunity based on anti-OVA-
specific T-cells. It was discovered that the amount of both OVA-specific T-cells and 
CD8+ were significantly higher in mice treated with Ad5Δ24-CpG. Due to this, 
Ad5Δ24-CpG is more suitable for vaccine platforms than the unmodified virus, because 
it has the oncolytic effect and it also stimulates the Toll-like receptor 9. (Cerullo et al. 
2012) 
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Figure 5. In vivo efficacy of Ad5Δ24-CpG in xenograft nude mice carrying A549 
tumor. Tumors were injected intratumorally with 1.0 x 10
8
 vp/tumor on day 0. (Cerullo 
et al. 2012) 
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Figure 6. In vivo efficacy of Ad5Δ24-CpG in immunocompetent C57BL/6 mice (n=4) 
carrying B16-OVA tumors. Tumors were injected intratumorally with 1.0 x 10
8
 
vp/tumor on day 0, 2 and 4. (Cerullo et al. 2012) 
 
In one recently published article a novel TNFα-expressing oncolytic adenovirus was 
studied, Ad5/3-D24-hTNFa. The TNFα gene was cloned into the adenoviral genome, 
hence infected cells (i.e. tumor cells) would produce this cytokine during the infection 
cycle of the virus. By this mean, a localized and sustained TNFα production in the 
tumor could be achieved. The efficacy and immunogenicity of this modified adenovirus 
was studied in vitro and in vivo. The Ad5/3-D24-hTNFa vector significantly slowed 
down the tumor growth compared to unmodified virus. Then an in vivo experiment was 
carried out using C57BL/6 mice bearing B16-OVA tumors. Interestingly, higher levels 
of OVA- specific CTLs, CD8
+
 lymphocytes and B-cells were observed in the Ad5/3-
D24-hTNFa treated mice compared to mice treated with unmodified virus. (Hirvinen et 
al. 2015) 
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4.5. Limitations of current approaches 
 
Promising results have been achieved with some treatments for melanoma and cancer, 
but there seems to be a lot of challenges to face. Current approaches at least as a 
monotherapy are not sufficient and better results have been achieved when therapies are 
combined. (Smith et al. 2008; Hodi et al. 2010; Schwartzentruber et al. 2011; Ellebaek 
et al. 2012) 
As discussed in chapter 3.1 the responses were improved when IL-2 was combined with 
peptide, adjuvant or TILs. Although they have synergistic effects to each other, the 
response in patients is still quite weak. (Smith et al. 2008; Schwartzentruber et al. 2011; 
Ellebaek et al. 2012)  
Tumor antigens can be used to direct the responses against the tumor by activating 
adaptive immune responses. These antigens have been used in the cancer therapy but 
they are not sufficiently effective for the treatment of tumor. Given as a monotherapy 
they have shown only low immunogenic effect (Schwartzentruber et al. 2011). Because 
of this they need strong adjuvants to increase the immune responses against a tumor. 
When peptides are combined with adjuvant they show improved antitumor efficacy 
(Schwartzentruber et al. 2011; Kruit et al. 2013). 
It has been pointed out that the oncolytic adenoviruses are potential antitumor agents for 
the cancer therapy. Their antitumor efficacy has been observed in several studies in 
mouse tumor models (Cerullo et al. 2012; Hirvinen et al. 2015). In addition to this, their 
safety and efficacy have been proved in clinical trials but the selectivity against tumor is 
still limited (Nemunaitis et al. 2000). Improvements of the selectivity and the antitumor 
efficacy have been tried by different modifications of the adenoviruses’ genome as was 
mentioned earlier in chapter 4.4. In some cases the antitumor efficacy has been shown 
to improve the immune responses against the tumor due to the modifications in the 
adenoviruses’ genome (Cerullo et al. 2012; Hirvinen et al. 2015).    
The important limitation which is related to the use of adenoviruses is high prevalence 
of pre-existing Ad5 neutralizing antibodies in human populations (Sumida et al. 2005). 
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This might limit the immunogenicity and decrease the effect of adenovirus (Ad5) gene 
therapy.  
 
 
5. PeptiCRAd 
 
PeptiCRAd is a cancer vaccine platform which consists of a conditionally replicating 
adenovirus (CRAd) and tumor-derived peptides (figure 7). In this system the virus acts 
as an adjuvant for the tumor-derived peptides capable of boosting the immunological 
response and actively killing tumor cells (Cerullo et al. 2012). 
In this study, I decided to use the Ad5Δ24-CpG virus which has deletion in E1A gene 
but it is also CpG- enriched in the E3 gene (Cerullo et al. 2012). Antitumoral effects of 
adenovirus containing deletion in E1A region has been published previously (Heise et 
al. 2000; Cerullo et al. 2012). In addition, as was mentioned in chapter 4.4, Ad5Δ24-
CpG virus can activate APC to more effective antigen presentation.  
The peptides are bound to the surface of the virus by electrochemical forces so that the 
adenoviruses are fully covered with the peptides. More precisely, to allow the peptides 
to interact with the negative surface of the adenovirus capsid, we added a poly lysine 
(poly-K) chain to the sequence of the peptides in order to make them positive at 
physiological pH. Hence, the positively charged tumor peptides are attached to the 
negatively charged capsid. When the complex gets into the cancer cells, it can replicate 
and produce new viral particles to infect other cancer cells. On the other side, we have 
also hypothesized that when the complex is uptaken by APCs the viral pathogen 
associated molecular patterns (PAMPs) stimulate the maturation of the APC while the 
tumor peptides are presented on the MHC-I to the T-cells.  
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Figure 7. The structure of the PeptiCRAd is comprised of the conditionally replicating 
adenovirus (CRAd), whose capsid is covered by tumor-derived peptides. Adenoviruses 
are consisted of icosahedral protein capsid which covers its linear DNA genome and 
core proteins. On the surface of capsid there are three important proteins hexon, penton 
and fiber that have crucial role in adenovirus entry into the cell. 
 
 
6. PRECLINICAL MODELS OF MELANOMA 
 
6.1. in vivo mouse models 
 
Before any drug treatment gain access to clinical studies the safety and efficacy must be 
assessed in cellular and animal models. The challenge is to get appropriate and 
predictive models. To study melanoma, different animal models are currently available. 
The choice of the appropriate model should be made depending on what characteristics 
are supposed to be studied. Animal models can be divided into subtypes including the 
syngeneic transplantation models, the xenograft models and the genetically modified 
animal models (Bobek et al. 2010). The syngeneic animal models can be used to study 
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the immune responses to the treatments, since these animals have a full immune system. 
The xenograft models present immunodeficient animal models so these are applicable to 
other studies.    
Several murine melanoma models have been developed to study drug treatments of 
melanoma. To study the immunological effects of the adenoviruses we need a syngeneic 
model bearing a murine tumor. In this context, the C57BL/6 mice implanted with the 
B16 melanoma cells are frequently used model (Cerullo et al. 2012; Hirvinen et al. 
2015).  
The B16 melanoma represents an important model and different cell lines have been 
derived from these tumors (e.g B16-F10 and B16-OVA). In most cases, the B16 cells 
are implanted subcutaneously and they form a palpable tumor under the skin in 5-10 
days after the implantation (Overwijk and Restifo 2001). It has been observed that B16 
cells express low levels of MHC class I and due to this it is considered to be a poor 
immunogenic model (Seliger et al. 2001). The B16-OVA, murine tumor cell line, 
expresses chicken ovalbumin protein that acts as a specific tumor antigen. The 
ovalbumin protein is processed endogenously, and the epitope SIINFEKL, presented on 
the major histocompatibility complex (MHC) class I, is able to be recognized by the 
immune system. 
 
 
7. AIM OF THE THESIS 
 
The aim of the experimental part was to investigate the efficacy of a new cancer vaccine 
platform: PeptiCRAd. PeptiCRAd was tested in vivo using immunocompetent C57BL/6 
mice bearing murine melanomas (B16-OVA). The cytopathic effects of PeptiCRAd 
were tested in vitro using in human adenocarcinoma epithelial cell line, A549.  
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8. MATERIALS AND METHODS 
 
The human lung adenocarcinoma epithelial cell line (A549) was purchased (ATCC; 
Manassas, VA, US). B16-OVA, the mouse melanoma cells, were obtained from Mayo 
Clinic (Rochester, MN, USA). The both cells were cultured in the low glucose 
Dulbecco's Modified Eagle Medium (DMEM; Lonza, Basel, CH) supplemented with 10 
% Fetal Bovine Serum (FBS), 1 % penicillin–streptomycin and 1 % L-glutamine 
(Glutamax™ Gibco, Life Technologies). The cells were grown in an incubator under 5 
% CO2 conditions and at 37 °C temperature. The cells were washed with phosphate 
buffered saline (PBS) and detached with Trypsine (TrypLE™; Gibco, Life 
Technologies). PolyK-SIINFEKL and SIINFEKL peptides were purchased from 
Zhejiang Ontores Biotechnologies Co. (Zhejiang, CN).  
 
8.1. Ad5Δ24 production  
 
8.1.1. Virus amplification 
 
For a virus amplification and a characterization A549 cells were cultured in 10 175 cm
2
 
cell culture flasks with DMEM (10 % FBS) and seeded at a density of 15000 cells/cm
2
. 
Four days after, the cells were infected with 30 multiplicity of infection (MOI) using a 
previously purified preparation of Ad5Δ24. The virus was diluted in DMEM (2 % FBS) 
to prepare the infection solution. After removing the media from the cells, those were 
incubated with the infection solution for 1 ½ hours in the incubator under 5 % CO2 
conditions and at 37 °C temperature. After the incubation, DMEM (10 % FBS) was 
added and the flasks were incubated at the same conditions. Cytopathic effects were 
followed under a microscope every day. After three days the cells were collected when 
showing almost 100 % cytopathic effects (CPE) and centrifuged (600 rpm, 10 min and 
at 4 °C). After discarding the supernatant, the pellets were resuspended in DMEM (2 % 
FBS) and the adenoviral particles were recovered from cells by freezing (-80 °C) and 
thawing (+37 °C) the cell suspension four times. The cell suspension was centrifuged at 
4000 rpm for 25 minutes at 4 °C. Afterwards the supernatant was collected into the 
Falcon tube (15ml) on ice.  
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8.1.2. Virus purification  
 
Cesium chloride (CsCl) gradient ultra-centrifugation was used to separate a cell debris 
and impurities from adenovirus particles. This experiment was carried out using two 
ultracentifuge runs (Beckman Coulter Optima L-80 XP). Before procedure the 
ultracentrifuge tubes were sterilized under UV-light for 10 minutes. The gradient was 
made of two densities of CsCl (1.33 g/cm3 and 1.45 g/cm3), cell-virus suspension and 
Hepes (5mM). First, 12 ml of CsCl (1.45 g/cm
3
) were added at the bottom of the tube, 
then 12 ml of CsCl (1.33 g/cm
3
) were added on the top of the more dense solution. The 
crude virus was then applied to the gradient. Initially, the sample was centrifuged for 2 
h 15 min at 20 000 rpm and at 4 °C temperature. After the centrifugation the virus was 
roughly separated from the cell debris, and the viral particles were visible in the 
gradient as a thick white band (figure 8). 
 
 
Figure 8. Viral preparation after the first centrifugation run. The virus band can be seen 
in the middle of the tube (the lowest white band between clear and pink layers). 
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After the centrifugation the virus band was collected into the Falcon tube on ice. The 
virus band was extracted carefully by side puncture using 22G needle and a syringe 
(3ml). The cesium chloride gradient was prepared as earlier, the collected virus was 
placed to the top of the tube and filled with Hepes (5mM). The second centrifugation 
was performed for 18 h at 27 000 rpm and at 4 °C temperature.  After the centrifugation 
the pure virus was in the middle of the Cesium chloride gradient (figure 9). The virus 
was collected from the tube as previously described and stored on the ice before the 
dialysis. 
 
 
Figure 9. Viral preparation after the second centrifugation run. The virus band is in the 
middle of the cesium chloride gradients. 
 
For purification of the virus from residues of CsCl, A195 dialysis buffer was prepared 
(table 1). All the reagents were diluted to water (MilliQ) and prepared buffer solution 
was sterilized by autoclave. 
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Table 1. The reagents and their concentrations in A195 dialysis buffer solution. 
Reagent final concentration 
Trizma® Base (Sigma Aldrich) 10 mM 
Sodium Chloride (NaCl) 75 mM 
Sucrose 5 % (w/v) 
Tween 80 0,02 % (w/v) 
MgCl · 6 H2O 1 mM 
EDTA, disodium salt (dihydrate) 100 µM 
Etax AA (99,5 %) 0,5 % (w/v) 
L-hystidine 10 mM 
 
The dialysis cassettes (Slide-A-lyzer dialysis cassette; 10000 MW cutoff; Life 
Technologies) were pre-wetted for 15 minutes with the dialysis buffer solution before 
the dialysis. The virus was injected to the dialysis membrane, attached to the floater and 
placed to the A195 buffer solution for 6 hours at 4 °C. After 6 hours the buffer solution 
was changed and the dialysis was continued overnight (17 hours). The pure virus was 
recovered from the dialysis cassette, aliquoted and stored at -80 °C temperature. 
 
8.2. Virus characterization 
 
To characterize Ad5Δ24, the viral concentration, the infectious titer, the total virus 
protein concentration and the genetic modifications were defined. The total virus 
concentration was determined by the spectrophotometric method. Being based on a 
measurement of DNA content, this method is not able to distinguish between the 
functional and the non-functional viral particles. For this reason, Immunocytochemistry 
method (ICC) was used to determine the infectious titer of the virus preparation, hence 
the functional viral particles. The total virus protein concentration was quantified by the 
Bradford assay and the genetic modifications of the virus by the Polymerase Chain 
reaction (PCR) method and the gel electrophoresis.  
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8.2.1. Virus titering 
 
Aliquotes of virus were thawed at a room temperature and incubated on a heating plate 
for 15 minutes at 95 °C (±2 °C). The virus vials were allowed to cool 30 minutes and 
then spinned-down carefully. The virus was diluted with the Virus Lysis Buffer (VLB). 
The VLB was prepared mixing 1x Tris-EDTA (pH 7.8) and 0.5 % Sodium dodecyl 
sulfate (SDS). The SDS was used to lyse the virus into its component proteins and 
DNA. To quantify the concentration of the viral particles in the virus preparation, the 
optical density (OD) was measured at 260, 280 and 320 nm wavelength. The DNA of 
the virus has absorbance maximum at 260 nm, while the virus proteins and possible 
contaminating proteins have higher absorbance. To this purpose five dilutions of virus 
(1:3, 1:5, 1:10, 1:50 and 1:100) in duplicates were prepared.  The samples and the 
blanks (VLB) were plated 80 µl into the 96 well plate. Absorbance was measured using 
the spectrophotometer (Varioskan™ Flash Multimode Reader, Thermo Scientific, 
USA). 
 
8.2.2. Protein concentration  
 
The protein concentration of the viral preparation was quantified by the 
spectrophotometry using Bradford assay (Bio-Rad dye reagent). The dye reagent was 
diluted five times water (MilliQ) and filtered with Millex®GP filter (0.22 µm). 
Albumin was used as a standard. Six dilutions of the albumin stock solution (1 mg/ml) 
were prepared in triplicates using A195 buffer. From four different concentration of the 
sample solutions were prepared duplicates (1:2, 1:5, 1:10 and undiluted virus). 10 µl of 
the standard solution and the samples were plated into the wells of a 96 microtiter plate. 
Afterwards, 200 µl diluted and filtered Bio-Rad dye reagent was added and mixed 
carefully with the samples. The plate was incubated in the room temperature for five 
minutes, hence the absorbance was measured at 590 nm with the spectrophotometer 
(Varioskan™ Flash Multimode Reader, Thermo Scientific, USA).  
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8.2.3. Infectious titer 
 
Infective amount of the virus was quantified using Immunocytochemistry assay (ICC). 
Cells (A549) were seeded to 24-well plate in DMEM (10 % FBS). The cell density was 
adjusted to 2.0 x 10
5
 cells per well in 500 µl. The cells were incubated at 37º C in a 5 % 
CO2 incubator overnight. The next day the cells were infected with four dilutions of 
Ad5Δ24- virus with five replicates per dilution. A dilution range (10-6 – 10-9) was 
selected to be suitable for the titer of virus. Dilutions were prepared using DMEM (2 % 
FBS) media. The growth medium in the wells was replaced with 500 µl of fresh DMEM 
(2 % FBS) and the infection solutions were added (100 µl) to each well, excluding 
controls. The plate was centrifuged for 90 minutes with 1000 rcf at 37 °C. After that 
plate was incubated at 37 °C in a 5 % CO2- incubator three days.  
After three days the old culture medium was removed carefully. The cells were fixed 
with ice-cold methanol (250 µl) and incubated for 10 minutes at room temperature. The 
methanol was removed and the cells were washed three times with PBS (300 µl) 
supplemented with 1 % bovine serum albumin (BSA). At first, the cells were stained 
with 250 µl of the mouse monoclonal anti-hexon (Novus Biologicals, Littleton, CO, 
USA) diluted 1:2000 with PBS (1 % BSA) and then incubated for one hour at room 
temperature protected from the light. After the incubation, the cells were washed three 
times with 300 µl of PBS (1 % BSA) and stained with the second antibody, biotin-
streptavidin-conjugated goat anti-mouse, diluted 1:500 with PBS (1 % BSA). The cells 
were incubated for one hour at room temperature protected from the light. After the 
incubation, the cells were washed three times with 300 µl of PBS (1 % BSA) and then 
incubated for 30 minutes at room temperature protected from the light with 250 µl of 
Extravidin-peroxidase (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:200 with PBS (1 
% BSA). The cells were washed three times with PBS (1 % BSA) and DAB-solution (3, 
3’-diaminobenzidine) was prepared according to the manufacturer’s instructions. The 
cells were incubated with 250 µl of DAB- solution for 5-10 minutes and formation of 
dark spots were observed under the microscope (figure 10). When the optimal signal to 
noise – ratio was achieved the reaction was quenched by adding 500 µl of PBS.   
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Figure 10. A549, human lung adenocarcinoma, cells infected with Ad5D24- virus were 
fixed after three days. After staining with two different antibodies, mouse monoclonal 
anti-hexon and biotin-streptavidin-conjugated goat anti-mouse, DAB- solution was 
added to form dark spots indicating virus infected cells.  
 
Dilution containing countable number of dark spots in each microscopic field was 
chosen and five images were taken (10x) from each well using a microscope (Evos® 
XL, AMG). Infected cells (i.e. dark spots) were counted and the infectious titer was 
calculated according to equation 1: 
𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑢𝑠 𝑡𝑖𝑡𝑒𝑟 = 𝑥 ∗ 
𝑤𝑒𝑙𝑙 𝑎𝑟𝑒𝑎 
𝑓𝑖𝑒𝑙𝑑 𝑎𝑟𝑒𝑎
 * 
1
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
∗  
1 𝑚𝑙
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
  (1) 
where x is average number of spots in each image, well area is surface area of one well 
on 24- well plate (190 mm
2
) and field area is surface area of each image (2.59 mm
2
).  
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8.2.4. Polymerase chain reaction to assess the integrity of the genome 
 
During the production of the virus some genetic modifications might occur. Therefore, 
we will use Polymerase chain reaction (PCR) and gel electrophoresis to detect any 
genetic mutation in the viral DNA. To break the viral capsid and release the DNA out, 
virus sample was incubated on hotplate at 100° C for 15 minutes and allowed to cool on 
ice. The Δ24- and the whole E3 region of adenoviruses were amplified using PCR (table 
3) and reagent solutions were prepared according to the table 4. Two samples of both 
regions and one control sample were prepared. In control sample template DNA was 
replaced with water (nuclease free, Thermo Scientific) and Δ24 region primers were 
used. The sequences of the primers which were used in the experiment are listed below 
(table 2): 
 
Table 2. The sequences of the Δ24- and the E3 region primers 
Primer Sequence 
 
Δ24 forward 
 
5’-GTC-CGG-TTT-CTA-TGC-CAA-AC-3’ 
 
Δ24 reverse 
 
5’-TCA-CCC-TCT-TCA-TCC-TCG-TC-3’ 
 
Transgene E3 forward 
 
5’-CAA-CCC-AGA-CGG-AGT-GAG-T-3’ 
 
Transgene E3 reverse 
 
5’-CCT-GAC-TTC-AAG-GTT-GTA-GC-3’ 
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Table 3. Thermocycling conditions for PCR 
Step Temperature (°C) Time 
Initial denaturation 98 45 sec 
 
35 cycles 
98 30 sec 
57 30 sec 
72 30 sec 
Final extension 72 10 min 
 
 
Table 4. The reagents of the samples for PCR (Thermo Scientific) 
Reagent Quantity (µl) 
water, nuclease free 31 
GC Buffer 10 
Primer, reverse 2.5 
Primer, forward 2.5 
dNTP mix 1 
Template DNA 2 
Phusion Polymerase 0.5 
 
 
Agarose gel electrophoresis method was used to visualize the cDNA. The gel was 
prepared by mixing 1x TAE (Tris-Acetate-EDTA) with agarose powder (Bioline) and 
stained with SYBR® safe DNA gel stain (Thermo Scientific). In this experiment 1 % 
agarose gel was used to separate E3 region and 2 % agarose gel for Δ24 region. 
Samples for electrophoresis were prepared by mixing colorant (6x Orange DNA loading 
dye, Thermo Scientific) and DNA sample. As a reference compound was used Gene 
Ruler 1 kb DNA ladder (Thermo Scientific) diluted with water (nuclease free, Thermo 
Scientific). The electrophoresis procedure was carried out using 100 V for one hour. 
 31 
 
DNA molecules formed bands in the gel representing molecules of different sizes. DNA 
was visualized using the gel imaging system (Molecular Imager®, Bio Rad).  
 
8.3. Cell viability assay 
 
Cytopathic effects of PeptiCRAd to A549 cells were studied by assessing the cell 
viability. Three different treatments were used in this experiment to infect the cells, 
PeptiCRAd, Ad5Δ24-CpG and polyK-SIINFEKL- peptide. The cell viability assay was 
carried out using four different concentrations of PeptiCRAd, Ad5Δ24-CpG and polyK-
SIINFEKL- peptide.  
Assay was performed on Greiner bio-one Cellstar® 96 well plates. The cell density was 
adjusted to 1.0 x 10
4
 cells per well. The cells were seeded in triplicate in 100µl of 
DMEM (5 % FBS) growth medium for each concentration and then incubated at 37 °C 
temperature overnight under 5 % CO2 conditions.  
The next day the cells were infected with four different dilutions of virus 0.1, 1, 10 and 
100 vp/cell (viral particles per cell) in 50 µl of DMEM (2 % FBS) in triplicates (figure 
11). For control samples was added only 50 µl of DMEM (2 % FBS).  
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Figure 11. The layout of the dilutions of viral particles (vp) per cell. 
 
After the infection, the well plate was incubated two hours at 37 °C temperature. 
Afterwards, 100 µl of DMEM (5 % FBS) was added to each well and incubated at 37 
°C until the day of assay. The cells were observed under the microscope every day to 
inspect the cytopathic effects. The growth media (DMEM 5 % FBS) was changed every 
other day.  
After seven days of the infection, when almost 100 % cytopathic effect was observed in 
the wells with the highest infectious conditions of (100 vp/cell), the cell viability was 
assayed by a one step MTT assay (MTS assay) according to manufacturer’s protocol 
(Cell Titer 96 Aqueous One Solution Cell Proliferation Assay; Promega, Nacka, 
Sweden). The growth media (DMEM 5 % FBS) was replaced with the fresh media. 
After this into each well 20 µl of MTS tetrazolium compound [3-(4, 5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] was added 
protected from the light. The well plate was incubated at 37 °C for 1 ½ hour and then 
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absorbance was measured at 490 nm wavelength using the spectrophotometer 
(Varioskan™ Flash Multimode Reader, Thermo Scientific, USA). 
8.4. In vivo experiment 
8.4.1. Implanting the melanoma cells 
The animal experiment was reviewed and approved by the Experimental Animal 
Committee of the University of Helsinki and the Provincial Government of Southern 
Finland. The animal model that was used for this experiment is the fully 
immunocompetent C57BL/6 female mice. The mice were purchased from Scanbur 
(Karlslunde, DK). These mice were kept in cages and there were food and water 
available all the time during the experiment. The tumor cell line that was used in this 
experiment was the B16-OVA murine melanoma cell line. In this in vivo experiment 3 x 
10
5
 B16-OVA melanoma cells were implanted subcutaneously into both flanks of the
mice. Afterwards the tumor growth was observed and measured. When the tumors 
reached an average diameter 3-5 mm, the treatment was started. Perpendicular tumor 
diameter was measured using a digital caliper.  
8.4.2. The treatment of tumor 
Mice were randomly split to five groups so that in each group there were seven to eight 
mice. The groups of study were: 
 The mice treated with Sodium Chloride (Mock)
 The mice treated with the peptide (SIINFEKL)
 The mice treated with the adenovirus (Ad5Δ24-CpG)
 The mice treated with the adenovirus and the peptide non complexed (Ad5Δ24-
CpG + SIINFEKL)
 The mice treated with the adenovirus complexed with the peptide (OVA-
PeptiCRAd) 
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The treatment consisted of three intratumoral (i.t) injections. Injections were given at 
day 0, day 2 and day 7. Day 0 was the day when the tumors had been grown to an 
injectable size (typically 3 mm of diameter) and the treatment was started. In this 
experiment the treatment started 9 days after tumor implantation. The viral dose was 1.0 
x 10
9
 viral particles in 50 µl for each of the tumors. The tumor size was measured every
other day and the tumor volume was calculated according to equation 2: 
𝑡𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 =
(𝑚𝑖𝑛𝑖𝑚𝑢𝑚 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)2 𝑥 (𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)
2
(2) 
The mice were euthanized if the primary tumor grew above 15 mm diameter or if they 
showed any sign of distress or pain.  
9. RESULTS
9.1. Virus characterization 
For the determination of Ad5Δ24- viral particles, the optical density of the virus 
samples was measured at 260, 280 and 320 nm wavelength. The absorbance was 
measured at 280 nm and 320 nm wavelength to observe possible interfering proteins. 
The absorbance results at 320 nm were used as a reference, while results at 280 nm 
compared to readings at 260 nm wavelength. As a quality parameter was used OD 
260/280 outcome. The preparation showed 3.22 x 10
12
 vp/ml as a viral titer.
To detect genetic mutations in Ad5Δ24- virus genome, PCR was used to amplify the 
Δ24 and E3 regions and gel electrophoresis to separate DNA from the sample. 
Previously studied virus sample was used as a reference for both Δ24 and E3 regions. 
Two Δ24- samples were tested using duplicates. In figure 12 it can be observed that the 
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bands of both Δ24 samples are identical with control sample and both E3 samples are 
identical between each other. Any genetic mutations were not observed.  
Figure 12. The Δ24- and the whole E3 region of adenoviruses were amplified using 
PCR. DNA was separated from the sample and visualized by gel electrophoresis. A= the 
samples of my virus prep, B= the previously studied virus samples (reference) 
9.2. In vitro experiment 
The results of cell viability assay are presented in figure 13 the number of viable cells 
was determined by measuring the absorbance at 490 nm wavelength. Blank-corrected 
value was calculated for each sample. The results are presented as a mean of triplicates 
for each concentration. The cell viability was measured seven days after infection. It can 
be observed in figure 13 that polyK-SIINFEKL- peptide treatment didn’t decrease the 
cell viability at any concentration. In adenovirus and complex groups the cell viability 
was lower at higher vp/cell ratio. When comparing these two groups, the mean cell 
viability was lower with adenovirus than complex at almost all dilutions. But the 
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variation within the groups is significant at lower dilutions. When the concentration was 
0.1 viral particles/cell the mean cell viability was the lowest in complex group.  
Figure 13. The effect on cell viability (A549 cell line) when PeptiCRAd (complex), 
polyK-SIINFEKL (peptide) and Ad5Δ24-CpG (Adenovirus) were applied on wells four 
different concentrations: 0.1 vp/cell, 1 vp/cell, 10 vp/cell and 100 vp/cell. Data are 
presented as the mean of cell viability (n=3) ± SD.  
9.3. In vivo experiment 
The volume of tumors were observed and measured over time and the results are 
presented in figure 14. Tumors grew steadily in each group until day 7. In Ad5Δ24-CpG 
and Mock groups tumors grew strongly after day 7. In SIINFEKL and PeptiCRAd 
groups the tumor growth became slower. When compared the tumor growth between 
Ad5Δ24-CpG, Ad5Δ24-CpG + SIINFEKL and PeptiCRAd, it can be seen that 
PeptiCRAd showed the strongest antitumor effect on the growth of established 
melanomas. In this group the treatment significantly slowed down the tumor growth 
compared to mock and the adenovirus treatment. In the end of experiment the tumor 
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volume was significantly smallest in PeptiCRAd group. In this experiment PeptiCRAd 
and SIINFEKL peptide seemed to control the tumor growth most. 
 
 
Figure 14. In vivo efficacy of PeptiCRAd. Mice bearing B16-OVA melanoma received 
PBS (Mock) or SIINFEKL or Ad5Δ24-CpG or Ad5Δ24-CpG + SIINFEKL or 
PeptiCRAd injections at day 0, 2 and day 7. Tumor growth was measured over time. 
Data are presented as the mean of tumor volume (mm
3
) ± SEM. (** P<0.01, *** 
P<0.001 by two way ANOVA with Bonferroni multiple comparison test). 
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Figure 15. The area under the curve was calculated for each tumor growth curve. 
 
The area under the curve (AUC) - values were calculated and data is presented in figure 
15. AUC values are related to the tumor volume of each group and these values 
correlate well with the tumor volume. In fact, the growth of the tumors treated with 
OVA-PeptiCRAd shows the lowest AUC, indicating a reduced growth compared to all 
the other groups. 
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10. DISCUSSION 
 
During my internship I learned how to amplify and characterize oncolytic adenoviruses. 
The virus production and characterization part were performed using a conventional 
serotype 5 adenovirus bearing the D24 deletion on the E1 gene. For the in vitro and in 
vivo efficacy evaluation we used a modified Ad5Δ24 enriched in CpG islands (Ad5Δ24-
CpG). This oncolytic virus has previously shown to have improved antitumor activity 
compared to the basic Ad5Δ24 (Cerullo et al. 2012).  
I characterized the adenovirus preparation to investigate if any recombination occurred 
in the viral genome and if any wild-type adenovirus was present within the preparation. 
Assessing the integrity of the genome and the contamination by wild-type adenovirus is 
an important step in the quality check process of virus production. First, unwanted 
rearrangement of the genome might impair the replication of the virus. Second, the 
presence of wild-type virus in the preparation might increase the risks of toxicity for the 
animals and the operation because the wild-type virus is able to replicate also in normal 
tissues (Bischoff et al. 1996). No mutations or contaminations from wild-type virus 
were observed in the viral preparation that I produced. 
 
10.1. In Vitro Experiment 
 
We demonstrated with MTS assay the cytopathic effects of Ad5Δ24-CpG and 
PeptiCRAd in A549 cell line. A549 cells are known to be sensitive to adenovirus 
infection, hence the amplification of adenoviruses is effective in these cells (Smith et al. 
1986). MTS tetrazolium compound can be metabolized to colorful formazan compound 
if the cells are metabolically active. Because this compound is colorful and it absorbs 
light we can measure the absorbance. The absorbance is directly proportional to the 
number of viable cells in culture.  
Cytolytic effects of adenoviruses to tumor cells have been pointed out in many studies 
(Cerullo et al. 2012; Hirvinen et al. 2015). In this experiment we showed that Ad5Δ24-
CpG and PeptiCRAd are able to enter A549 cells and lyse them. The probable 
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mechanism of which Ad5Δ24-CpG and PeptiCRAd enter the cells is via CAR- receptor. 
A549 cells have been reported to express high amount (over 80 %) of CAR receptors 
(Wang et al. 2014). Previously, it has been proposed that CAR receptors are primary 
binding sites for Ad5- viruses (Bergelson et al. 1997). In addition, also the αvβ-integrins 
promote Ad5 virus internalization into the A549 cells (Davison et al. 2001).  
In this experiment the modified peptide, polyK-SIINFEKL was tested to find out if it 
has cytotoxic effects to A549 cells. As expected, polyK-SIINFEKL peptide didn’t affect 
to the viability of A549 cells. In this experiment the cytopathic effects of Ad5Δ24-CpG 
to A549 cells were more pronounced than PeptiCRAd. This effect was clearly observed 
at the strongest dilution (100 vp/cell). The difference could result from weaker infection 
of the cells due to the weaker attachment and internalization into the cells. Another 
reason for weaker cytolytic effect could be that the replication in PeptiCRAd is not as 
effective as in Ad5Δ24-CpG.  
 In this experiment it was pointed out that Ad5Δ24-CpG virus and PeptiCRAd can 
infect, replicate and finally kill the A549 cells.  
. 
10.2. In Vivo Experiment 
 
To study the antitumor efficacy of the PeptiCRAd in vivo, B16-OVA cells were 
implanted subcutaneously to the flanks of C57BL/6 mice. SIINFEKL peptide and 
ovalbumin can both bind to the H2-K
b 
MHC class I molecule that murine antigen 
presenting cells express. The surface of our virus Ad5Δ24-CpG is covered with polyK-
SIINFEKL peptide, which is epitope derived from OVA and presented by H2-K
b
 MHC-
I molecule. 
The immunocompetent mice, C57BL/6, that used in this experiment have full immune 
system, so they are able to produce immune responses against the antigen and the 
viruses. Using this tumor model we will assess the ability of the PeptiCRAd to elicit a 
tumor-specific immune response. These melanoma cells express ovalbumin, an antigen 
that we can target and mice have the same MHC complex as B16 melanoma.   
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We demonstrated that the PeptiCRAd significantly slowed down the tumor growth after 
priming and boosting injections compared to other treatments. In this experiment it was 
shown that co-administration of adenovirus and peptide as a complex (PeptiCRAd) 
inhibited tumor growth more effective than when adenovirus and peptide were given 
not attached to each other. AUC values were also calculated and the results correlate 
with the tumor volume. Because the virus that we used in this experiment is human 
adenovirus it can’t replicate in murine melanoma cell line. Due to this it is unable to 
produce new viral particles and directly kill mouse tumor cells. This indicates that the 
effect to tumor growth is affected via immune responses against tumor cells and not 
cytolytic effect should be seen. This is the significant limitation of this model, because 
it doesn’t show the full antitumor effects of adenoviruses. 
Antitumor effects of Ad5Δ24-CpG has been studied earlier using the same tumor 
model, C57BL/6 mice bearing B16-OVA cells (Cerullo et al. 2012). It was observed 
that Ad5Δ24-CpG viruses are able to produce OVA-spesific T-cells. It was also pointed 
out that Ad5Δ24-CpG is able to inhibit the tumor growth. In our experiment Ad5Δ24-
CpG didn’t show antitumor effects in vivo when it was used as an only treatment.  
In this experiment we managed to control the tumor growth clearly in PeptiCRAd 
group. In addition, mice treated with SIINFEKL peptide alone and combined with 
Ad5Δ24-CpG were also shown to have antitumor effects. Because SIINFEKL peptide 
doesn’t kill the tumor cells as was presented in vitro experiment with modified polyK- 
SIINFEKL-peptide, there must be some other mechanisms to affect the tumor growth. 
This indicates that there are some immune responses against SIINFEKL- antigen. As 
mentioned earlier SIINFEKL peptide can be presented to the T-cells by APCs and 
activate adaptive immune system.  
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11. CONCLUSIONS 
 
The aim of the thesis was to evaluate the antitumor efficacy of new cancer vaccine 
platform, PeptiCRAd. 
PeptiCRAd showed cytopathic effects to A549 cells in vitro and antitumor effects upon 
B16-OVA tumors in vivo. Although PeptiCRAd showed weaker antitumor effects in 
vitro than Ad5Δ24-CpG, I observed an increased antitumor efficacy in vivo. As a 
conclusion based on the in vivo and in vitro results, PeptiCRAd has antitumor efficacy 
and it could be potential cancer vaccine platform. 
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